ER-positive, HER2-negative Breast Cancer
8 clinical trials · Condition
◉ Watch ER-positive, HER2-negative Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 (NCT05364255) | AstraZeneca | 2022-05-10 |
| A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer (NCT04993430) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-10-26 |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (NCT04964934) | AstraZeneca | 2021-06-30 |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (NCT04711252) | AstraZeneca | 2021-01-28 |
| Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women (NCT01709370) | Organisation for Oncology and Translational Research | 2012-02-01 |
Track ER-positive, HER2-negative Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.